Zhao Yan's new drug (06127.HK) obtained a cumulative reduction of approximately 422,400 shares by the board of directors and senior management.

Intelligence Finance APP News, Zhaoyan New Drug (06127.HK) announced that the company's directors, deputy general manager Sun Yunxia, director, general manager, board secretary Gao Dapeng, director, deputy general manager Gu Jingliang, supervisor Li Ye, and CFO Yu Aishui disclosed a reduction plan on September 9, 2025. Starting from the date of the announcement of the reduction plan, 15 trading days later, from September 30, 2025 to November 28, 2025, they will reduce their holdings through block trading or centralized bidding on the Shanghai Stock Exchange in a total amount of no more than 674,700 shares, 72,100 shares, 67,400 shares, 25,600 shares, and 8,500 shares, totaling no more than 848,300 shares, which is 0.1132% of the company's current total share capital. As of November 28, 2025, Sun Yunxia, Gao Dapeng, Gu Jingliang, Li Ye, and Yu Aishui have reduced holdings of 319,940 shares, 25,500 shares, 66,500 shares, 2,000 shares, and 8,500 shares respectively, and the reduction plan period has expired.